CymaBay Pipeline

Home / Pipeline

Overview

Our pipeline is focused on developing therapies for liver and other chronic diseases with high unmet medical need. In addition to evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH), our phase 3 ready program for arhalofenate in gout has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. Additionally, we have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

  Pre-Clinical Phase 1 Phase 2 Phase 3
Internal Programs
Seladelpar
Primary Biliary Cholangitis
Seladelpar
Non-alcoholic Steatohepatitis
MBX-2982

(GPR 119 agonist)

Undisclosed
CB-001

(GPR 120 agonist)

Undisclosed
Licensed Programs
Arhalofenate
Gout   (U.S.)